Dimensional Fund Advisors LP Sells 1,500,953 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

Dimensional Fund Advisors LP decreased its position in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 8.3% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 16,495,009 shares of the company's stock after selling 1,500,953 shares during the quarter. Dimensional Fund Advisors LP owned about 3.34% of Elanco Animal Health worth $238,020,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. ORG Partners LLC acquired a new stake in Elanco Animal Health in the 2nd quarter worth approximately $31,000. nVerses Capital LLC acquired a new stake in Elanco Animal Health in the 2nd quarter worth approximately $32,000. Jones Financial Companies Lllp acquired a new stake in Elanco Animal Health in the 4th quarter worth approximately $37,000. Global Financial Private Client LLC acquired a new stake in Elanco Animal Health in the 1st quarter worth approximately $72,000. Finally, Meeder Advisory Services Inc. acquired a new stake in Elanco Animal Health in the 2nd quarter worth approximately $154,000. Institutional investors own 97.48% of the company's stock.

Insider Activity

In other news, CEO Jeffrey N. Simmons acquired 100,000 shares of the stock in a transaction dated Monday, August 12th. The shares were acquired at an average cost of $13.01 per share, for a total transaction of $1,301,000.00. Following the completion of the transaction, the chief executive officer now owns 145,000 shares in the company, valued at approximately $1,886,450. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CEO Jeffrey N. Simmons purchased 100,000 shares of the stock in a transaction on Monday, August 12th. The shares were purchased at an average cost of $13.01 per share, for a total transaction of $1,301,000.00. Following the completion of the transaction, the chief executive officer now directly owns 145,000 shares of the company's stock, valued at approximately $1,886,450. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Michael J. Harrington purchased 3,500 shares of the stock in a transaction on Thursday, August 22nd. The stock was bought at an average price of $14.85 per share, for a total transaction of $51,975.00. Following the completion of the transaction, the director now directly owns 81,094 shares of the company's stock, valued at $1,204,245.90. The disclosure for this purchase can be found here. 0.57% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities research analysts recently weighed in on ELAN shares. Morgan Stanley lowered Elanco Animal Health from an "overweight" rating to an "equal weight" rating and reduced their target price for the stock from $17.00 to $15.00 in a report on Thursday. Barclays cut their price target on Elanco Animal Health from $23.00 to $21.00 and set an "overweight" rating for the company in a report on Friday, June 28th. Stifel Nicolaus reiterated a "buy" rating and set a $20.00 price target on shares of Elanco Animal Health in a report on Thursday. Finally, Piper Sandler cut their price target on Elanco Animal Health from $19.00 to $16.00 and set a "neutral" rating for the company in a report on Monday, July 1st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $17.29.

Elanco Animal Health Stock Performance

Shares of ELAN traded up $0.41 on Thursday, reaching $15.07. 17,388,729 shares of the stock traded hands, compared to its average volume of 4,806,717. The firm has a market cap of $7.44 billion, a price-to-earnings ratio of -5.68, a P/E/G ratio of 1.44 and a beta of 1.40. The company has a debt-to-equity ratio of 0.92, a current ratio of 2.93 and a quick ratio of 1.75. Elanco Animal Health Incorporated has a 12 month low of $8.52 and a 12 month high of $18.80. The stock's 50-day moving average price is $13.92 and its 200-day moving average price is $15.17.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The company reported $0.30 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.24 by $0.06. The business had revenue of $1.18 billion for the quarter, compared to analysts' expectations of $1.15 billion. Elanco Animal Health had a positive return on equity of 7.29% and a negative net margin of 27.94%. Elanco Animal Health's quarterly revenue was up 12.0% on a year-over-year basis. During the same period in the previous year, the business posted $0.18 earnings per share. Equities analysts forecast that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.